Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Drug Review Europe Regulation

New EU Filings

  • Data

Executive Summary

Aprocitentan, Idorsia/Janssen Biotech’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with resistant hypertension, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.

You may also be interested in...



Concizumab, Elranatamab & Talquetamab Among New EU Filings At EMA

The European Medicines Agency has started reviewing a new batch of medicines for potential pan-EU marketing approval.

Ophthalmic Bevacizumab & CRISPR-Based Gene Therapy Among Latest EU Filings

Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.

Rozanolixizumab & Biosimilar Ustekinumab Among Raft Of New Drugs Filed In EU

The European Medicines Agency’s latest list of drugs under review for potential marketing approval includes a second generalized myasthenia gravis treatment from UCB and what could become the first biosimilar version of Stelara in the EU.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Drug Review Europe Regulation
Latest Headlines

Pharma Industry On How To Tackle EU Regulatory & Reimbursement Barriers To Digital Therapeutics

What Would An EU ‘Regulatory Sandbox’ Bring To New Drug Development?

US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month

Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings

See All
UsernamePublicRestriction

Register

PS147782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By